Table III.
Adverse events (grade ≥III) in the review.
| First author (Refs.) | Hypertension | Thromboembolic disease | Hemorrhage | Thrombocytopenia | Fatigue | Leukopenia | Neutropenia | Lymphopenia | Wound diseases | Visceral perforation | Proteinuria |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chinot (17) | 52 (11.3) vs. 10 (2.2) | 58 (12.6) vs. 42 (9.3) | 15 (3.3) vs. 8 (1.8) | 69 (15) vs. 44 (9.8) | 34 (7.4) vs. 21 (4.7) | NA | NA | NA | 15 (3.3) vs. 7 (1.6) | 5 (1.1) vs. 1 (0.2) | 25 (5.4) vs. 0 |
| Gilbert (18) | |||||||||||
| DCR | 4 (1.3) vs. 1 (0.3) | 14 (4.6) vs. 12 (4.0) | 0 vs. 1 (0.3) | 31 (10.2) vs. 23 (7.7) | 7 (2.3) vs. 8 (2.7) | 16 (5.3) vs. 7 (2.3) | 22 (7.3) vs. 11 (3.7) | 32 (10.5) vs. 27 (9.0) | 3 (1) vs. 1 (0.3) | 1 (0.3) vs. 1 (0.3) | NA |
| DMP | 11 (4.2) vs. 2 (0.9) | 22 (7.7) vs. 11 (4.7) | 4 (1.6) vs. 2 (0.9) | 29 (11.1) vs. 27 (11.7) | 34 (13.1) vs. 21 (9.0) | 22 (8.5) vs. 14 (6.0) | 26 (10.7) vs. 12 (5.1) | 34 (13.1) vs. 31 (13.4) | 4 (1.6) vs. 2 (0.9) | 3 (1.2) vs. 1 (0.4) | NA |
| Lai (16) | 8 (11) | 13 (19) | 5 (7) | NA | 14 (20) | NA | NA | NA | 4 (6) | 2 (3) | 8 (11) |
Data are n (%). DCR, during chemoradiotherapy; DMP, during the maintenance phase; NA, not available.